Schalast | M&A in Healthcare & Life Sciences

The healthcare, pharmaceutical and life sciences sector is highly regulated, presenting significant barriers to entry. Therefore, specialised expertise is essential for successfully executing cross-border M&A transactions. 

Our clients benefit from our extensive experience in implementing complex M&A projects, including pre- and post-restructuring of companies, holding and consortium agreements, post-merger integration and integrated financing processes. We also handle non-performing loans and MBO/MBI situations, ensuring comprehensive support throughout the entire transaction process. 

We also understand the sector-specific challenges and requirements. The legal nuances in this industry significantly impact due diligence, contract drafting, structuring, and ultimately, the successful completion of a transaction. 

Intangible assets such as trademarks, patents, copyrights and licences play a crucial role. Additionally, specific regulatory considerations must be taken into account, as these can greatly affect a company’s valuation. 

Additionally, we have particular expertise in advising on the entire lifecycle of start-ups in the healthcare and life sciences sector. This includes providing strategic advice to financial investors such as business angels, accelerators, incubators and venture capitalists, from early-stage investments to later stages and exits. 

With our industry-specific knowledge, we successfully support medium-sized and large enterprises, as well as biotech and medtech start-ups, in M&A and private equity transactions. Our services also encompass advising clients on restructuring projects, regulatory issues related to acquisitions, and compliance matters. 

 

Learn more about our Corporate/M&A practice group.